Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

The United Laboratories International Holdings (ULIHF) Stock Price & Analysis

ULIHF Stock Chart & Stats

$0.87-$0.01(-0.57%)
At close: 4:00 PM EDT
$0.95$1$1.05$1.131 Aug16 Sep30 Sep12 Oct
Day’s Range
$0.86 - $0.89
52-Week Range
$0.82 - $1.88
Previous Close
$0.88
Volume
2
Average Volume (3M)
85
Market Cap
$1.72B
Enterprise Value
$10.04B
Total Cash (Recent Filing)
$11.73B
Total Debt (Recent Filing)
$5.95B
Price to Earnings (P/E)
20.8
Beta
-0.28
Next Earnings
Mar 30, 2027 (Est.)
EPS Estimate
0.03
Last Dividend Ex-Date
Jul 09, 2026
Dividend Yield
4.37%

Bulls Say, Bears Say

Bulls Say

Diversified Pharmaceutical Model

The combination of finished medicines and APIs gives the company multiple routes to generate revenue across the pharmaceutical value chain. Internal API use can support product supply, while external API sales broaden the customer base and diversify exposure across healthcare markets.

Healthy Gross Margin

A gross margin near 42% indicates that the portfolio still retains meaningful product-level economics despite recent pressure. Maintaining this level provides room to fund research, regulatory compliance, manufacturing capabilities, and commercial activity while supporting resilience through demand fluctuations.

Conservative Leverage And Growing Assets

Moderate leverage and a steadily expanding asset base provide financial flexibility for a pharmaceutical business that requires sustained investment in products and operations. A stronger equity foundation can reduce reliance on borrowing and improve the company’s ability to manage cyclical earnings pressure.

Bears Say

Revenue Contraction

The shift from multi-year expansion to a material revenue decline signals weaker near-term demand, market penetration, or product contribution. If the contraction persists, it could reduce operating leverage, limit reinvestment capacity, and make it harder to sustain the company’s prior growth trajectory.

Margin And Return Compression

Lower margins and ROE show that the company is generating less profit from both sales and its capital base. Persistent compression would weaken earnings quality, reduce the payoff from continued investment, and constrain the company’s ability to compound returns even if absolute profitability remains positive.

Weak And Volatile Cash Conversion

Weak conversion of accounting profit into free cash flow makes earnings less supportive of internally funded growth and capital returns. Volatility also complicates planning, leaving less dependable cash available for research, capacity investment, debt management, or shareholder distributions.

The United Laboratories International Holdings News

ULIHF FAQ

What was The United Laboratories International Holdings’s price range in the past 12 months?
The United Laboratories International Holdings lowest stock price was $0.82 and its highest was $1.88 in the past 12 months.
What is The United Laboratories International Holdings’s market cap?
The United Laboratories International Holdings’s market cap is $1.72B.
When is The United Laboratories International Holdings’s upcoming earnings report date?
The United Laboratories International Holdings’s next earnings report is estimated for Mar 30, 2027 (not yet confirmed), which is in 148 days.
How were The United Laboratories International Holdings’s earnings last quarter?
The United Laboratories International Holdings released its earnings results on Aug 31, 2026. The company reported $0.026 earnings per share for the quarter, beating the consensus estimate of $0.019 by $0.007.
Is The United Laboratories International Holdings overvalued?
According to Wall Street analysts The United Laboratories International Holdings’s price is currently Undervalued.
Does The United Laboratories International Holdings pay dividends?
The United Laboratories International Holdings pays a Annually dividend of $0.038 which represents an annual dividend yield of 4.37%. See more information on The United Laboratories International Holdings dividends here
What is The United Laboratories International Holdings’s EPS estimate?
The United Laboratories International Holdings’s EPS estimate is 0.03.
How many shares outstanding does The United Laboratories International Holdings have?
The United Laboratories International Holdings has 1,970,276,500 shares outstanding.
What happened to The United Laboratories International Holdings’s price movement after its last earnings report?
The United Laboratories International Holdings reported an EPS of $0.026 in its last earnings report, beating expectations of $0.019. Following the earnings report the stock price went down -3.07%.
Which hedge fund is a major shareholder of The United Laboratories International Holdings?
Currently, no hedge funds are holding shares in ULIHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology